SCHEMBL8016162

SCHEMBL8016162

CC1CN(C(=O)OC(C)(C)C)c2ccccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.63
KDM1A O60341 1/20 0.47
BCHE P06276 1/20 0.46
DRD2 P14416 1/20 0.45
DRD4 P21917 1/20 0.45
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
RORC P51449 2/20 0.41
GPR119 Q8TDV5 1/20 0.40
TSHR P16473 1/20 0.40
ABHD6 Q9BV23 1/20 0.40
NAMPT P43490 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8562821 0.86 NOTUM (0.46) NOTUMKDM1ABCHEKDM4EHDAC1
SCHEMBL3406623 0.86 NOTUM (0.46) NOTUMKDM1ABCHEKDM4EHDAC1
SCHEMBL6648372 0.86 KDM1A (0.54) NOTUMKDM1ABCHEKDM4EMEN1
SCHEMBL7004085 0.85 KDM1A (0.50) NOTUMKDM1ABCHEKDM4EMAPK1
SCHEMBL14222127 0.84 KDM1A (0.46) NOTUMKDM1ABCHEHDAC1HDAC6
SCHEMBL30346095 0.84 KDM1A (0.52) NOTUMKDM1ABCHEMAPK1HDAC1
SCHEMBL3707225 0.84 KDM1A (0.52) NOTUMKDM1ABCHEMAPK1HDAC1
SCHEMBL29651255 0.83 KDM1A (0.44) NOTUMKDM1ABCHEKDM4EMEN1
SCHEMBL3695799 0.83 KDM1A (0.44) NOTUMKDM1ABCHEKDM4EMEN1
SCHEMBL5560266 0.82 KDM1A (0.44) NOTUMKDM1ABCHEMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234920-A1 Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-07-27 US disclosed
US-20230234920-A1 Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-07-27 US disclosed
WO-2009102574-A1 QUINOLIZIDINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS MERCK & CO., INC. (US) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234920-A1 Azirine Containing Compounds as Anti-Angiogenesis Agents and a Process for the Preparation Thereof FLT1, PGF, KDR NOTUM 2718/4885KDM1A 881/4885BCHE 2963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.